Clinical Trials Search
LungMAP: A Master Protocol to Evaluate Biomarker-Driven Therapies And Immunotherapies In Previously-Treated Non-Small Cell Lung Cancer(Lung-MAP Screening Study)
Master Protocol (LungMAP) PRIMARY OBJECTIVE The primary objective of this screening study is to test patient specimens to determine eligibility for participation in the biomarker-driven and non-matched sub-studies included within the Lung-MAP umbrella protocol. SECONDARY OBJECTIVES Screening Success Rate Objective To evaluate the screen success rate defined as the percentage of screened patients that register for a therapeutic sub-study. Screen success rates will be evaluated for the total screened population and by the subset of patients screened following progression on previous therapy or pre-screened on current therapy. Translational Medicine Objectives 1. To evaluate circulating tumor DNA (ctDNA) and compare to the FMI Foundation tissue molecular profiling results in patients who submit a new biopsy for screening. 2. To establish a tissue/blood repository. Ancillary Study S1400GEN Objectives The Lung-MAP Screening Study includes an ancillary study evaluating patient and physician attitudes regarding the return of somatic mutation findings suggestive of a germline mutation. Participation in this study is optional. PRIMARY OBJECTIVE To evaluate patient attitudes and preferences about return of somatic mutation findings suggestive of a germline mutation in the Lung-MAP Screening Study. SECONDARY OBJECTIVES 1. To evaluate Lung-MAP study physician attitudes and preferences about return of somatic mutation findings suggestive of a germline mutation in the Lung-MAP Screening Study. 2. To evaluate Lung-MAP patients and study physicians knowledge of cancer genomics. 3. To evaluate Lung-MAP patients and study physicians knowledge of the design of the Lung-MAP Screening Study. 4. To explore whether physician and patient knowledge of cancer genomics and attitudes and preferences about return of genomic profiling findings are correlated.
AG-014447 (Rucaparib); Alimta (Pemetrexed); Avelumab (); BMN-673 (Talazoparib); CO-338 (Rucaparib); Gemzar (gemcitabine); IMC-1121B (Ramucirumab); MSB00100718C (Avelumab); PF-01367338-BW (Rucaparib); Pembrolizumab (Keytruda); Pemetrexed (); Ramucirumab (); Rucaparib (); Selpercatinib (); Talazoparib (); Taxotere (docetaxel); docetaxel (); gemcitabine ()
> Patients must have pathologically proven non-small cell lung cancer (all histologic types) confirmed by tumor biopsy and/or fine-needle aspiration. Disease must be Stage IV as defined in Section 4.0, or recurrent. The primary diagnosis of non-small cell lung cancer should be established using the current WHO/IASLC-classification of Thoracic Malignancies. All histologies, including mixed, are allowed.